BioCryst Pharmaceuticals, Inc. (BCRX) Set to Announce Quarterly Earnings on Monday
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is set to issue its quarterly earnings data before the market opens on Monday, November 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The company’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. On average, analysts expect BioCryst Pharmaceuticals to post $-0.71 EPS for the current fiscal year and $-0.76 EPS for the next fiscal year.
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) opened at 4.42 on Monday. The firm has a 50-day moving average price of $5.12 and a 200-day moving average price of $5.42. The company’s market capitalization is $355.49 million. BioCryst Pharmaceuticals, Inc. has a one year low of $3.75 and a one year high of $9.25.
A number of research analysts have recently commented on BCRX shares. Royal Bank Of Canada started coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. J P Morgan Chase & Co raised their target price on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Jefferies Group LLC upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $5.00 to $7.00 in a research note on Wednesday, September 6th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $8.78.
In related news, Director Fred E. Cohen sold 54,250 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 5.80% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.